Lesniewski-Kmak, K., Moiseenko, V., Saunders, M., Wasan, H., Argiles, G., Borg, C., Creemers, G., Fedyanin, M., Glynne-Jones, R., Pfeiffer, P., Punt, C., Stroyakovskiy, D., Ten Tije, A., Van de Wouw, A., Kanehisa, A., Fougeray, R., Busto, N. L., Amellal, N., & Van Cutsem, E. (n.d.). o-022Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysis. Annals of oncology, 29, . http://access.bl.uk/ark:/81055/vdc_100095481750.0x00003f